Skip to Content
Merck
  • Relationship between the severity of acne vulgaris and antimicrobial resistance of bacteria isolated from acne lesions in a hospital in Japan.

Relationship between the severity of acne vulgaris and antimicrobial resistance of bacteria isolated from acne lesions in a hospital in Japan.

Journal of medical microbiology (2014-02-14)
Keisuke Nakase, Hidemasa Nakaminami, Yuko Takenaka, Nobukazu Hayashi, Makoto Kawashima, Norihisa Noguchi
ABSTRACT

Propionibacterium acnes and Staphylococcus epidermidis are normal skin inhabitants that are frequently isolated from lesions caused by acne, and these micro-organisms are considered to contribute to the inflammation of acne. In the present study, we examined the antimicrobial susceptibilities and resistance mechanisms of P. acnes and S. epidermidis isolated from patients with acne vulgaris in a university hospital in Japan from 2009 to 2010. Additionally, we analysed the relationship between the antimicrobial resistance of P. acnes and the severity of acne vulgaris. Some P. acnes strains (18.8 %; 13/69) were resistant to clindamycin. All strains had a mutation in the 23S rRNA gene, except for one strain that expressed erm(X) encoding a 23S rRNA methylase. Tetracycline-resistant P. acnes strains were found to represent 4.3 % (3/69) of the strains, and this resistance was caused by a mutation in the 16S rRNA gene. Furthermore, three strains with reduced susceptibility to nadifloxacin (MIC = 16 µg ml(-1)) were detected. When analysing the correlation between the antimicrobial resistance of P. acnes and S. epidermidis, more than 80 % of the patients who carried clindamycin-resistant P. acnes also carried clindamycin-resistant S. epidermidis. However, no epidemic strain that exhibited antimicrobial resistance was detected in the P. acnes strains when analysed by PFGE. Therefore, our results suggest that the antimicrobial resistance of P. acnes is closely related to antimicrobial therapy. Additionally, those P. acnes strains tended to be frequently found in severe acne patients rather than in mild acne patients. Consequently, the data support a relationship between using antimicrobial agents and the emergence of antimicrobial resistance.

MATERIALS
Product Number
Brand
Product Description

Sigma-Aldrich
Erythromycin, potency: ≥850 μg per mg
Sigma-Aldrich
Erythromycin, BioReagent, suitable for cell culture
Sigma-Aldrich
Erythromycin, tested according to Ph. Eur.
Sigma-Aldrich
Minocycline hydrochloride, powder
Sigma-Aldrich
Chloramphenicol, ≥98% (HPLC)
Sigma-Aldrich
Chloramphenicol, BioReagent, suitable for plant cell culture
Sigma-Aldrich
Chloramphenicol, meets USP testing specifications
Sigma-Aldrich
Levofloxacin, 98.0-102.0% anhydrous basis (HPLC)
Supelco
Levofloxacin, analytical standard
USP
Ciprofloxacin hydrochloride, United States Pharmacopeia (USP) Reference Standard
Ciprofloxacin hydrochloride for peak identification, European Pharmacopoeia (EP) Reference Standard
USP
Oxacillin sodium, United States Pharmacopeia (USP) Reference Standard
USP
Clarithromycin Identity, United States Pharmacopeia (USP) Reference Standard
Chloramphenicol, European Pharmacopoeia (EP) Reference Standard
Ciprofloxacin hydrochloride, European Pharmacopoeia (EP) Reference Standard
Supelco
Erythromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Supelco
Ciprofloxacin HCl, Pharmaceutical Secondary Standard; Certified Reference Material
USP
Erythromycin, United States Pharmacopeia (USP) Reference Standard
Erythromycin, for microbiological assay, European Pharmacopoeia (EP) Reference Standard
Supelco
Chloramphenicol, VETRANAL®, analytical standard
Sigma-Aldrich
Clarithromycin, ≥95% (HPLC)
Supelco
Clarithromycin, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
Clarithromycin, 96.0-102.0% (HPLC)
Clarithromycin for peak identification, European Pharmacopoeia (EP) Reference Standard
Clarithromycin, European Pharmacopoeia (EP) Reference Standard
USP
Clarithromycin, United States Pharmacopeia (USP) Reference Standard